IMMUNIC, INC. Files 8-K on Financials
Ticker: IMUX · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
IMMUNIC, INC. filed an 8-K on Nov 13, 2025, reporting on financial condition and results.
AI Summary
On November 13, 2025, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.
Why It Matters
This 8-K filing indicates IMMUNIC, INC. is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting financial condition and results, with no immediate indication of significant negative events.
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- November 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1200 Avenue of the Americas, Suite 200 New York, NY 10036 (address) — Principal executive offices
- (332) 255-9818 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for IMMUNIC, INC.?
The primary purpose of this 8-K filing is to report on IMMUNIC, INC.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed or effective?
The report was filed as of November 13, 2025, and the date of the earliest event reported is also November 13, 2025.
In which U.S. state is IMMUNIC, INC. incorporated?
IMMUNIC, INC. is incorporated in Delaware.
What is the principal executive office address for IMMUNIC, INC.?
The principal executive office address is 1200 Avenue of the Americas, Suite 200, New York, NY 10036.
What is the telephone number listed for IMMUNIC, INC.?
The registrant's telephone number, including area code, is (332) 255-9818.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-11-13 07:26:52
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In
Filing Documents
- e664954_8k-immunic.htm (8-K) — 22KB
- e664954_ex99-1.htm (EX-99.1) — 69KB
- image_001.jpg (GRAPHIC) — 6KB
- 0001193805-25-001570.txt ( ) — 274KB
- imux-20251113.xsd (EX-101.SCH) — 3KB
- imux-20251113_lab.xml (EX-101.LAB) — 33KB
- imux-20251113_pre.xml (EX-101.PRE) — 22KB
- e664954_8k-immunic_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On November 13, 2025, Immunic, Inc. (the "Company") issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company's financial results for the quarter ended September 30, 2025 and providing a corporate update (the "Press Release"). The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company's filings with the Securities and Exchange Commission (the "SEC"), except as shall be expressly set forth by specific reference in any such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits Exhibit Description 99.1 Press Release, dated November 13, 2025. 104 Cover Page to this Current Report on Form 8-K in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: November 13, 2025 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer